Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Flux Therapeutics
Cambridge, Massachusetts, United Statesflux-therapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Flux Therapeutics develops next-generation genetic medicines using a proprietary platform based on Targeted Ubiquitin Modulators. Their lead program targets PRPF8 for rare congenital disorders, currently in the discovery/preclinical stage. No clinical results have been published as of early 2025[1][3].
- Therapeutic areas
- OncologyRare DiseasesNeurology
- Modalities
- Fusion proteinGenetic medicinesTargeted Ubiquitin Modulators (TUMs)
- Industry
- Biotech
Beyond the preview
Go deeper on Flux Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flux Therapeutics.